Does MNKD pay a dividend and is it safe?

MannKind Corporation (MNKD) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / MNKD / dividends

AVLN (44) AMPH (72) VSTM (36) JANX (37) ⌘ Pro Terminal →

MannKind Corporation (MNKD) Dividend Safety Gauge & 10-Year DRIP Compounder

$3.65 +4.29% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.67

MannKind Corporation (MNKD) carries a Roarable Rating of D+ (Sell) with 56/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 56/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.4% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $1.13B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MNKD Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MNKD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, MannKind Corporation (NASDAQ: MNKD) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $3.65 (+4.29% 1D, market cap $1.13B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, MNKD ranks #200 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MNKD compare to AVLN and AMPH in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MNKD carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of 92.3%, and ROIC of 54.5%. By comparison, AVLN (Avalyn Pharma Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC —, cap $1.14B) and AMPH (Amphastar Pharmaceuticals Inc.) posts a B grade (72/100 RQD, P/E 11.7x, ROIC 9.0%, cap $1.18B). Among the 5-stock peer group, AMPH leads on earnings multiple (11.7x) while MNKD leads on capital efficiency (54.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MNKD?

▼

Per MNKD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000899460), MannKind Corporation generated $349.0M in revenue (+22.2% YoY), $5.9M in net income, and $13.7M in free cash flow against $792.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.67 (+0.58%)🧬 Disciplined Float (-0.32% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 3.9% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 56/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.4% avg 90D alpha vs SPY • 51.8% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-0.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MNKD)Realized 20D OHLCV Swing Band: ±10.4%

Deterministic 5-Pillar Attribution (56/100 Composite)

🔍 WHY MNKD SCORES 56/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+14/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 3.9% FCF Margin ($13.7M FCF) & 92.3% Gross Margin

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+13/20 pts (23% of score)

SEC Form 4 / 13F Thermometer: 65% Net Buy • Disciplined Float (-0.32% YoY Shares)

▼ #1 Drag / Risk Factor: Macro Regime Fit8/20 pts (-12 pt drag)

Macro rate sensitivity & RSI-14 (55.6) create a -12 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$3.05+1.6% Next Q

Q2 (-2Q)

Grade C-$3.10+6.1% Next Q

Q3 (-1Q)

Grade C-$3.29+10.9% Next Q

Current

Grade D+$3.65-0.4% Hist 90D α

Trajectory: D (48) → D+ (56)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the MNKD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 56/100 (D+) score, MNKD faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($3.56) or 200D SMA ($3.71) invalidates the momentum regime and cuts Target Base ($3.62) toward Bear Floor ($2.82).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MNKD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “MNKD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 56%NO 44%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (12.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $33,350

Est. Year-10 Shareholder Yield: $200/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.3K

Yr 1

$12.7K

Yr 2

$14.4K

Yr 3

$16.2K

Yr 4

$18.3K

Yr 5

$20.6K

Yr 6

$23.2K

Yr 7

$26.2K

Yr 8

$29.6K

Yr 9

$33.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MNKD)

✓Walkthrough of MNKD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MNKD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +29.89%▼ DESCENDING CHANNEL

2026-11-03O $3.50H $3.65L $3.50C $3.65VOL 2.01M

RES: $4.20SUP: $2.70SMA50: $3.56SMA200: $3.71

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MNKD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MNKD Butterfly Map → + Track MNKD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

23.7%/yr Implied 5Y Growth

vs. +22.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MNKD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MNKD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MNKD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MNKD)

Health Care Rank #200 of 1016 ⚔️ AVLN vs MNKD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MNKD vs. AVLN, AMPH, VSTM, JANX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, MannKind Corporation (MNKD) ranks #200 by composite RQD confidence (56/100, grade D+) and #342 by equity capitalization ($1.13B). Within this direct 5-issuer industry benchmark cohort, AMPH leads on earnings valuation at 11.7x trailing P/E, while MNKD leads on capital efficiency and profitability with 54.5% ROIC and 92.3% gross margin. AMPH currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with MNKD at 56/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MNKD ACTIVE MannKind Corporation	D+	56/100	—	92.3%	54.5%	+4.29%	$1.13B	Benchmark Subject
AVLN Avalyn Pharma Inc.	D	44/100	—	—	—	-0.12%	$1.14B	/avln-vs-mnkd →
AMPH Amphastar Pharmaceuticals Inc.	B	72/100	11.7x	49.5%	9.0%	-2.49%	$1.18B	/amph-vs-mnkd →
VSTM Verastem Inc.	D-	36/100	—	—	-35.0%	-1.64%	$1.18B	/vstm-vs-mnkd →
JANX Janux Therapeutics Inc.	D-	37/100	—	—	-13.8%	-0.06%	$1.07B	/janx-vs-mnkd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000899460

In its most recent audited fiscal period (FY2025, filed 2025-12-31), MannKind Corporation (MNKD) reported GAAP revenue of $349.0M (+22.2% vs. FY2024 revenue of $285.5M , and +75.4% cumulative change since FY2023) , GAAP net income of $5.9M, operating cash flow of $18.3M, and free cash flow of $13.7M (-58.3% YoY). On the balance sheet, MNKD closed FY2025 with $792.2M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$349.0M	$5.9M	$18.3M	$13.7M	$792.2M	—
FY2024 (FY)	2024-12-31	$285.5M	$27.6M	$42.5M	$32.8M	$393.8M	—
FY2023 (FY)	2023-12-31	$199.0M	-$11.9M	$34.1M	$34.1M	—	—

3. MNKD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MNKD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does MNKD compare to AVLN and AMPH in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for MNKD?

Where is MNKD trading relative to its 50-day, 200-day, and 52-week technical levels?

MNKD last traded at $3.65 (+4.29% on volume of 3,175,147 shares), positioning the stock +2.53% above its 50-day simple moving average ($3.56) and -1.62% below its 200-day simple moving average ($3.71). Across its 52-week range of $2.23 to $6.51, MNKD sits at the 33.2% percentile with a 14-day RSI of 55.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±10.4% ($3.27 to $4.03).

Direct Sub-Reports: MNKD RQD Cockpit MNKD 12M Forecast MNKD Earnings & Move MNKD Dividends & DRIP MNKD Insiders & 13F MNKD Whale Options MNKD Profit Sankey MNKD News & Why

ROARABLE RATING BRIEF • RQD 56/100 (D+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

MNKD — MannKind Corporation: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:30:37Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

MNKD scores 55 out of 100 (letter grade D+), with the verdict "Roarable Sell — Weak Fundamentals / Trim." The five pillars are:

Fundamental Cash Engine (14/20): this pillar reflects ROIC of 54.5% and an FCF yield of 1.22%. The high ROIC contrasts with a thin 1.22% FCF yield, meaning the return on invested capital is not translating into proportionate cash returns to a buyer at the current price.
Whale / 13F Flow (8/20): institutional accumulation and options positioning score weakly.
Insider Conviction (13/20): SEC Form 4 and Congressional PTR cluster flow score moderately. Individual transactions are not itemized in the source data.
Macro Regime Fit (8/20): beta of 1.0 and sector sensitivity score weakly, indicating limited defensive character relative to the market.
Forensic Balance Sheet (12/20): Altman Z of 0.2 is a distress-zone reading, Piotroski F of 7/9 is a relatively healthy signal, and Debt/Equity of 0.5 is moderate. The conflict between a distressed Altman reading and a strong Piotroski reading is a key tension for an investor to weigh.

For a prospective investor evaluating the stock today, the rating implies that upside depends on the cash engine converting into free cash flow and on the balance sheet stabilizing, while the weak macro-fit and flow scores suggest limited institutional tailwind. The 55 score and "Trim" verdict frame the stock as one where risk currently outweighs the visible fundamental support.

2. Business Model, Unit Margins & SEC Financial Trajectory

MannKind Corporation (MNKD) is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry..1B. Reported revenue for FY 2025 was $349.0M.

Per the market data, gross margin is 92.3%, operating margin 11.1%, and net margin 1.7%, with ROIC at 54.5%. The Altman Z-Score is 0.2 and the Piotroski F-Score is 7/9, with Debt/Equity at 0.5. Revenue grew from $199.0M in FY 2023 to $349.0M in FY 2025, while net income fell from $27.6M in FY 2024 to $5.9M in FY 2025. Cash rose from $46.3M to $74.9M over the same span.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case: ROIC of 54.5% and cash rising from $46.3M to $74.9M indicate the operating engine is generating returns on capital despite a weak overall rating. With Fundamental Cash Engine at 14/20 (ROIC 54.5%, FCF yield 1.22%) and Institutional Whale Flow at 9/20, sustained execution supports upside toward the top of the $2.23 – $6.51 52-week range.
🐻 Primary Bear Case: An Altman Z-Score of 0.2 combined with net income falling to $5.9M in FY 2025 signals financial distress risk alongside a 1.22% FCF yield. Investors must weigh current valuation and 24.6x EV/EBITDA against 11.1% operating margins and a 1.00 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are —

Key Question #1: What are the reported EPS and trailing P/E figures, given that the financials table lists EPS as N/A and P/E as unavailable?
Key Question #2: What is the company's debt balance, given that debt is N/A across all reported periods despite a stated Debt/Equity of 0.5?
Key Question #3: Why did net income decline from $27.6M in FY 2024 to $5.9M in FY 2025 while revenue and operating income moved in differing directions?

MNKD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for MannKind Corporation (MNKD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MNKD Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 20h ago

MannKind Corporation (MNKD) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 23h ago

MannKind Corporation (MNKD) Interactive Stock Chart - Yahoo Finance

Yahoo! Finance Canada report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A heart-failure injector delivers a full dose in under 10 seconds. Urine output was similar to treatment into a vein.

Stock Titan report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Manila Times • 1d ago

MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026

The Manila Times report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Does MannKind (MNKD) Have a Differentiated Cardiorenal Strategy or Just Incremental Delivery Innovation?

Yahoo Finance report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

MannKind stock sets November 5 date for third-quarter results

ad-hoc-news.de report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.dars.gov.et/ • 1d ago

MNKD Q2 2026 Earnings: Wider-Than-Expected Loss Drives Modest Share Decline - Downward Estimate Revision

https://www.dars.gov.et/ report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

MannKind to Participate in the Chardan Healthcare Conference

Yahoo Finance report covering MannKind Corporation (MNKD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MNKD Bull vs. Bear Conversation Board — What's Your Call at $3.65?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MNKD 🐻 33% BEARISH CONVICTION

MI MidwestValue Fundamental Long-Only 🐂 BULLISH 🎯 Target: $4.38 (+25.1%)

📌 Pinned Debate

ROIC of 54.5% and cash rising from $46.3M to $74.9M indicate the operating engine is generating returns on capital despite a weak overa

Don't sleep on MNKD's setup in Health Care. ROIC of 54.5% and cash rising from $46.3M to $74.9M indicate the operating engine is generating returns on capital despite a weak overall rating.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (56/100) backs up the fundamental quality.

SectorRotator 🐂 BULL

@MidwestValue Agree on the RQD 56/100 quality, though with 1.0 beta I'm scaling in with half-size at $3.50 and keeping dry powder in case we test $3.26.

SK SkepticalCFA Fundamental Contrarian 🐻 BEARISH 🎯 Target: $2.77 (-20.9%)

Spot @ $3.50

An Altman Z-Score of 0.2 combined with net income falling to $5.9M in FY 2025 signals financial distress risk alongside a 1.22% FCF yie

Here is the bear case nobody on the bull side wants to address on MNKD: An Altman Z-Score of 0.2 combined with net income falling to $5.9M in FY 2025 signals financial distress risk alongside a 1.22% FCF yield.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.